MELBOURNE (AUSTRALIA) 27 November 2019: Invion Limited (ASX:...

MELBOURNE (AUSTRALIA) 27 November 2019: Invion Limited (ASX: IVX) (“Invion” or
“Company”) is pleased to announce the results from a pre-clinical study undertaken by
Hudson Institute of Medical Research.
The study used the first batch of Australian-made PhotosoftTM compound on mice with
ovarian cancer. Researchers at Hudson Institute analysed both immediate and medium-term
effects on tumours and observed the following:
• PhotosoftTM caused the immediate and specific death of tumour tissue, with no
apparent adverse effects in the surrounding healthy tissues.
• The size of the tumours in animals treated with PhotosoftTM Technology reduced to less
than half of their original size over a three-week period.
Importantly, Hudson Institute observed that tumour destruction was accompanied by an
influx of immune cells, indicating an anti-tumour immune response.
This is significant because current cancer treatments, such as chemotherapy, can kill healthy
cells and supress the body’s natural ability to fight infections.
This pre-clinical study marks the first scientific demonstration of the PhotosoftTM Technology in
a clinically relevant model and supports Hudson Institute’s original laboratory findings that
PhotosoftTM can rapidly kill cancer cells in vitro (outside of a living organism).
Dr Andrew Stephens, head of the Ovarian Cancer Research at Hudson Institute said: "These
results suggest that PhotosoftTM Technology may be an effective method to achieve
targeted tumour destruction. Over the coming months we will be working with the
PhotosoftTM Technology to characterise how tumour destruction and immune response are
linked, paving the way for clinical trials using PhotosoftTM Technology as a cancer therapy.”
Ovarian cancer is a devasting disease and new treatment options are badly needed.
Invion Limited ABN 76 094 730 417
722 High Street, East Kew, VIC 3102 Australia
P: +61 3 9081 6005 W: www.inviongroup.com
ASX ANNOUNCEMENT
“There are 1,500 new cases of ovarian cancer in Australia every year with around 4,000 to
5,000 Australians currently living with the disease. Internationally, there are around 240,000
new cases a year,” said Craig Newton, Chief Executive Officer of Invion.
“The grim reality is that nearly half of those diagnosed with the cancer will succumb to the
disease within five years of the diagnosis. We are hoping that Photo-Dynamic therapy (PDT)
can help address this challenge.”
Invion is developing an optimised version of PhotosoftTM called IVX-PDT, which is better suited
to large-scale GMP manufacturing while meeting clinical and regulatory requirements.
Data from Hudson Institute’s study with the PhotosoftTM Technology supports the view that
IVX-PDT can potentially be used to treat a range of solid cancers.
As previously announced to the market, Invion will be commencing Phase 1b human trials of
IVX-PDT to treat skin cancer, while Peter MacCallum Cancer Institute will be commencing
studies using IVX-PDT for the treatment of ano-genital cancer in 2020.